NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

NOVO.B.DK

462.75

-0.53%↓

COLO.B.DK

693.4

-1.08%↓

GMAB.DK

1,278

-0.23%↓

HLUNB.DK

31.88

+0.57%↑

AMBUB.DK

114.3

0%↓

Search

Zealand Pharma A-S

Open

462.8 0.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

449

Max

480.8

Belangrijke statistieken

By Trading Economics

Inkomsten

-25M

-291M

Verkoop

4.6M

9.1M

EPS

-4.12

Winstmarge

-3,213.715

Werknemers

335

EBITDA

8.1M

-253M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+25.15% upside

Dividenden

By Dow Jones

Volgende Winsten

15 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-13B

37B

Vorige openingsprijs

461.93

Vorige sluitingsprijs

462.8

Zealand Pharma A-S Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mrt 2025, 09:23 UTC

Belangrijke Marktbewegers

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 dec 2024, 09:22 UTC

Belangrijke Marktbewegers

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 mrt 2025, 16:34 UTC

Top Nieuws

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mrt 2025, 08:18 UTC

Marktinformatie

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Peer Vergelijking

Prijswijziging

Zealand Pharma A-S Prognose

Koersdoel

By TipRanks

25.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 270.582 DKK  25.15%

Hoogste 270.568 DKK

Laagste 270.568 DKK

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Zealand Pharma A-S - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

0

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.